Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Annovis Bio, Inc. (ANVS)
Company Research
Source: Yahoo! Finance
developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson's disease (PD). Topline efficacy data is expected in June. The Phase III study was completed in 4Q 2023 with an original plan for data announcement in 1Q 2024, however the Company faced a delay in the process of data cleaning beyond the original prognosis. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis, explains in detail the reason behind this delay: "When we reached the point of unblinding the data for the PD Phase III study, we discovered an unexpected issue: too many plasma samples showed no presence of buntanetap. We were expecting 33% blank samples from the placebo group, but we saw over 50% blank samples. We were afraid that we had mixed up bottles and that patients weren't given what they were supposed to. If that had happened, the study would have been worthless. We prompt
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Bio Files Patent for New Composition of Matter for Buntanetap [Yahoo! Finance]Yahoo! Finance
- Annovis Bio Files Patent for New Composition of Matter for BuntanetapGlobeNewswire
- Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson's Disease Data [Yahoo! Finance]Yahoo! Finance
- Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease DataGlobeNewswire
- Annovis Bio Highlights New Alzheimer's Data at the Alzheimer's Association International Conference® 2024 [Yahoo! Finance]Yahoo! Finance
ANVS
Earnings
- 5/10/24 - Beat
ANVS
Sec Filings
- 6/21/24 - Form S-8
- 6/13/24 - Form 8-K
- 6/11/24 - Form 8-K
- ANVS's page on the SEC website